|
Bedford Laboratories Announces Product Acqusition of CAFCIT (caffeine citrate) Injection and CAFCIT (caffeine citrate) Oral Solution
Bedford, OH - January 3, 2008 - Bedford Laboratories™, a division of Ben Venue Laboratories Inc., announced the acquisition of CAFCIT® (caffeine citrate) Injection and CAFCIT® (caffeine citrate) Oral Solution from Mead Johnson & Company. Bedford Laboratories is now the reference listed drug holder. CAFCIT® (caffeine citrate) is indicated for short term treatment of apnea in premature infants between 28 and <33 weeks gestational age. "The acquisition of CAFCIT® demonstrates our continued commitment to build the most comprehensive and cost effective line of injectable products in the pharmaceutical industry. We are proud to offer a branded product at a generic price'" said David Gaugh, Vice President and General Manager of Bedford Laboratories. Bedford Laboratories will supply latex free CAFCIT® (caffeine citrate) Injection and CAFCIT® (caffeine citrate) Oral Solution as a sterile liquid in the following presentations: - Injection: 60 mg/3 mL single-use vials individually boxed
- Oral Solution: 60 mg/3 mL single-use vials, 10 vials per child-resistant container
Prescribing information is available upon request from the Bedford Laboratories' professional services department, (800) 521-5169, or from the company's web site, www.bedfordlabs.com. |
